DPP4 and benign prostatic hyperplasia: The top scoring ligand obtained via SWISS-SIMILARITY was durasteride, an antiandrogenic compound used to treat symptomatic benign prostatic hyperplasia, with − 9.3 kcal/mol binding energy and the lowest scoring ligand was sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used to manage type 2 diabetes melitus, with − 8.2 kcal/mol binding energy score (Wishart et al. 2018).